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Mexiletine, l-methyl-Z- (2,6-xylyloxy)ethylamine hydrochloride (Mexi- 
til@ ), has been shown to suppress markedly ventricular rhythm disorders [l- 
61. Effective serum levels of mexiletine range from ca. 0.5 to 2.0 pg/ml [2- 
4,7,8]. Although the antiarrhythmic efficacy of mexiletine is not correlated 
directly with its serum level [ 3,4,7,8], the determination of the drug is rec- 
ommended when adverse effects occur, when drug therapy is ineffective in 
order to differentiate failure of therapy from suboptimal dosing, in patients 
with cirrhosis of the liver, or in order to check a patient’s compliance. 
Gas chromatographic (GC ) [9-121 and high-performance liquid chroma- 
tographic (HPLC) methods [ 13-231 have been widely used for the determi- 
nation of serum or plasma levels of mexiletine. GC methods are sensitive and 
specific but rather time-consuming, and require equipment that is not rou- 
tinely available in clinical laboratories. Most HPLC methods need either flu- 
orescence detection [ 13,16,19,20,23] or derivatization [ 14,16,18,19,20,23], and 
only some use UV detection with no need for either [ 15,17,21,22]. 
The aim of this study was to develop an HPLC assay for the simultaneous 
determination of mexiletine hydrochloride and mexiletine metabolites. The 
method had to be rapid, simple and accurate in the therapeutic range and in- 
expensive, to allow for easy monitoring of the drug in clinical practice. 
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EXPERIMENTAL 
Chemicals and reagents 
Mexiletine, mexiletine metabolite 1 (KOE 2259-0X) [ 1- (2-hydroxy- 
methyl-6-methylphenoxy)-2aminopropaneoxalate], metabolite 2 (KOE 2127- 
CL) [ 1- (2,6-dimethyl-4-hydroxy) -2-amino-propane hydrochloride] and the 
internal standard (KOE 768~CL) [ 1- (2,4_dimethylphenoxy) -2-aminopro- 
pane hydrochloride ] were provided by Boehringer Ingelheim (Ingelheim, 
F.R.G. ); acetonitrile, hydrochloric acid, triethylamine, dichloromethane and 
sodium hydroxide were obtained from Merck (Darmstadt, F.R.G.); l-octane- 
sulphonic acid (PIC B-8 low-UV reagent) and dibutylamine phosphate (PIC 
D-4 reagent) came from Waters Assoc. (Eschborn, F.R.G.); butylamine was 
obtained from Fluka (Buchs, Switzerland). 
Instruments 
The chromatographic system consisted of a Model 721 system controller, a 
510 HPLC pump, a Wisp 710B injector block, a Lambda-Max Model 481 vari- 
able-wavelength detector and a Data Module Model 730, all from Waters Assoc. 
Chromatographic conditions 
The analysis was performed using a Shandon Hypersil CPS (CN) reversed- 
phase column (250 mm x 4.6 mm I.D., particle size 5 pm) (Grom, Herrenberg, 
F.R.G.) at room temperature. The mobile phase consisted of 95% A (973.5 ml 
of water, 25 ml of PIC B-8 low-UV reagent, 1 ml of butylamine, 0.5 ml of PIC 
D-4 reagent) and 5% B (acetonitrile). The flow-rate was 2.0 ml/min. The 
column effluent was monitored at 215 nm, using a detector range of 0.02 a.u.f.s. 
and a chart speed of 0.4 cm/min. The injection volume was 200 ~1. 
Standards 
Two stock standard solutions were prepared, containing 20 pg/ml each of 
mexiletine hydrochloride, mexiletine metabolites and internal standard (I.S.) 
in 0.01 M hydrochloric acid. The solutions were stable for at least two months 
if stored at 4’ C. A standard working solution was obtained by combining ali- 
quots of the stock solutions and diluting with hydrochloric acid in concentra- 
tion of 2.0 lug/ml for either mexiletine hydrochloride, mexiletine metabolites 
or the I.S. 
Sample collections 
Serum was obtained by centrifugation at 900 g for 10 min. Twenty-two serum 
samples from normal volunteers (twelve male, ten female) were pooled (nor- 
mal pool). Twenty-four serum samples from patients (sixteen male, eight fe- 
male) treated with cardiovascular drugs, such as acebutolol, atenolol, betaxo- 
101, metoprolol, pindolol, sotalol, digoxin, nifedipine, verapamil, amiodarone, 
flecainide, propafenone, quinidine, phenprocoumone, acenocoumarol, acetyl- 
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salicylic acid, dipyridamol, sulfinpyrazone, spironolactone, furosemide, hy- 
drochlorothiazide and triamterene, were pooled in four pools (patient pools). 
Twenty serum samples from twenty patients (seventeen male, three female) 
treated with mexiletine (360-1440 mg per day) were analysed individually. 
Extraction procedure 
A 1.75ml volume of dichloromethane, 0.25 ml of triethylamine, 1.0 ml of 
serum, 100 ~1 of 1 M sodium hydroxide and 100 ~1 of the I.$. stock solution 
were placed in a glass centrifuge tube (Kgstner, Ttibingen, F.R.G. ) . The tube 
was closed with a stopper (Sarstedt, Niirmbrecht, F.R.G.), shaken (by slow 
rotation) for 20 min and centrifuged at 3600 g for 10 min. Subsequently the 
serum phase was discarded. Then 1.0 ml of the dichloromethane-triethylamine 
phase was transferred to a clean glass tube and evaporated to dryness at room 
temperature under a stream of nitrogen. The residue was redissolved in 500 ~1 
of 0.01 M hydrochloric acid. 
Linearity test 
The linearity of the chromatographic procedure was tested for mexiletine 
hydrochloride, mexiletine metabolites and the IS. by analysing six standard 
solutions with the concentrations 4.0, 2.0, 1.0, 0.5, 0.25 and 0.125 ,ug/ml for 
each of the components. The linearity test of the entire procedure was done 
with the same standard solutions. The amount of each standard required to 
reach concentrations in the range 0.125-4.0 pug/ml was introduced into a glass 
centrifuge tube, and 1.0 ml of the normal pool serum was added. Subsequently 
the spiked serum samples were extracted and chromatographed. 
Recovery 
The recovery was determined by comparing the peak areas of mexiletine 
hydrochloride, mexiletine metabolites and the I.$. obtained by analysing a 
spiked serum sample ( 100 ~1 of each stock solution standard plus 1.0 ml of the 
normal pool) with the peak areas obtained by direct injection of the standard 
working solution (2.0 ,ug/ml each of mexiletine hydrochloride, mexiletine me- 
tabolites and the IS.). 
Quantification 
The determination of the concentration of mexiletine hydrochloride and its 
metabolites in the serum was based on calibration graphs obtained from stan- 
dard solutions (0.125, 0.25, 0.5, 1.0, 2.0 and 4.0 pug/ml). The lower limit of 
quantification was 0.05 pg/ml for mexiletine and 0.02 pg/ml for its metabo- 
lites. Since the calibration graph was linear and the calibration was stable for 
three months, the calculation was performed with the 2.0 pg/ml of each of the 
standard compounds, using the following formula: 
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concentration of mexiletine in sample (pug/ml ) 
peak area of mexiletine (or metabolites) in sample = 
peak area of external standard 
X 
recovery of’I9Z. in sample ’ 2 
The recoveries of mexiletine, its metabolites and the IS. were shown to be 
the same within ca. 5%. 
RESULTS 
For the standards, as well as for the entire procedure, the linearity test showed 
a linear relationship between concentration and peak area for the total range 
tested. The recoveries (mean + S.D.) were 98.5 2 2.3% for mexiletine hydro- 
chloride, 99.92 8.2% for mexiletine metabolite 1, 96.7%6.6% for mexiletine 
metabolite 2 and 95.8 +_ 3.6% for the IS. (mean +_ SD. of ten determinations; 
the technical error of the apparatus was less than 1% for mexiletine, mexiletine 
metabolites and the I.S. 1. 
TABLE I 
SERUM LEVELS OF MEXILETINE HYDROCHLORIDE AND ITS METABOLITES IN 
PATIENTS TREATED CHRONICALLY WITH MEXILETINE 
Patient 
No. 
Oral dose of 
mexiletine 
hydrochloride 
per&y bid 
Serum level before mexiletine administration (pg/ml) 
Mexiletine Metabolite 1 Metabolite 2 
hydrochloride 
1 360" 1.00 0.10 0.04 
2 4006 0.89 0.16 0.30 
3 4006 0.74 <0.02 0.29 
4 4006 0.74 1.19 0.04 
5 600b 0.20 0.72 0.06 
6 600b 0.96 0.29 0.28 
7 600b 0.55 0.44 0.46 
8 600b 1.33 -co.02 co.02 
9 600b 1.23 0.60 0.14 
10 720" 1.01 0.39 <0.02 
11 720" 3.28 0.08 co.02 
12 720" 1.71 0.29 0.08 
13 720" 1.19 0.56 <0.02 
14 720" 2.20 0.38 0.39 
15 800b 2.31 0.77 co.02 
16 1080" 2.87 0.26 0.48 
17 1200b 1.94 0.04 0.49 
18 1200b 9 06 
20 1440" 
“Slow-release formulation. 
bInstant-release formulation. 
2.69 0.16 0.22 
2.01 0.16 0.72 
4.83 0.39 0.75 
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Fig. 1. Chromatograms of a blank from the normal pool (A), of a standard working solution (B ) 
and of the serum of a patient receiving mexiletine (C ) . 
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Fig. 2. Comparison of serum concentration of mexiletine hydrochloride determined by the present 
HPLC method and by the method used by Bioscentia (r=0.9650, n=20). 
We did not observe any cardiovascular substances as interfering peaks in the 
patients’ pools. The individual levels of mexiletine hydrochloride and mexile- 
tine metabolites (level before mexiletine administration) are shown in Table 
I. A typical chromatogram obtained from the analysis of a serum sample of a 
patient receiving mexiletine hydrochloride is shown in Fig. 1. A comparison of 
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the results from twenty serum samples analysed either in the laboratories of 
Bioscentia (Ingelheim, F.R.G.) (by HPLC with derivatization and fluores- 
cence detection; modification of the methods of Gupta and Lew [ 201 and Kelly 
et al. [ 211) and in our laboratory (by the present HPLC method) is shown in 
Fig. 2. 
The coefficients of variation (n= 10) were 2.3% for mexiletine, 8.2% for 
metabolite 1 and 6.8% for metabolite 2. 
DISCUSSION 
The majority of HPLC methods allows the determination of mexiletine only 
[13-l&18-231 or the determination of mexiletine enantiomers [ 18,231. The 
HPLC method of Farid and White [ 161 allows the additional determination 
of the mexiletine metabolites hydroxymethylmexiletine and p-hydroxymexi- 
letine, and that of Filipek et al. [ 171 the determination of the same two me- 
tabolites, but not the simultaneous determination of mexiletine. Recoveries of 
mexiletine and the I.S. and the limit of detection of mexiletine as given in the 
literature are listed in Table II. Recovery of hydroxymethylmexiletine was 85% 
[ 161 and 90% [ 171 and of p-hydroxymexiletine 88% [ 161 and 96% [ 171. The 
limit of detection was 0.005 [ 161 or 0.05 m/ml [ 171. 
The present HPLC method for the simultaneous assay of mexiletine and 
mexiletine metabolite serum levels yields a nearly complete recovery of mexi- 
letine, its metabolites and the I.S. from serum and a sufficiently low detection 
limit using UV detection at 215 nm with no need for fluorescence detection or 
TABLE II 
RECOVERY OF MEXILETINE AND INTERNAL STANDARD AND LIMIT OF DETEC- 
TION OF MEXILETINE 
Recovery ( % ) 
Mexiletine I.S. 
Limit of 
detection 
(,&ml) 
Reference 
46-69 
8’7 
81 
>90 
>90 
75-80 
>90 
68-78 
98 
0.05 
49-74 0.01 
101 0.1 
0.005 
0.05 
0.001 
>90 0.2 
72-87 0.05 
0.005 
96 0.05 
13 
14 
15 
16 
18 
19 
20 
21 
22 
23 
Present method 
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derivatization. No cardiovascular substance or endogenous substance was ob- 
served as an interfering peak, and an excellent correlation with an established 
HPLC method was demonstrated. 
In conclusion, this HPLC method is suitable for the clinical management of 
patients and for research into the effect of mexiletine metabolites on side- 
effects and efficacy. Measurements can be performed in every laboratory pos- 
sessing an HPLC system with a variable-wavelength UV detector without the 
need for additional equipment. 
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